

## LATEX-ENHANCED IMMUNOTURBIDIMETRIC ASSAY FOR THE DETERMINATION OF 11-DEHYDRO THROMBOXANE B2 IN URINE AS NEW ANALYTICAL TOOL FOR THE STUDY OF ASPIRIN EFFECTIVENESS

G Shanbhag, L Young, P McGivern, P Lowry, E Benchikh, S McElhatton, RI McConnell, J Campbell, SP FitzGerald  
Randox Laboratories Limited, Crumlin, United Kingdom



### INTRODUCTION

Activated and aggregated platelets play a key role in the pathogenesis of cardiovascular disease. An important part of antiplatelet therapy in cardiovascular disease is aspirin, but its effectiveness varies among individuals. Activated platelets produce a potent vasoconstrictor and inducer of platelet aggregation: thromboxane A<sub>2</sub>(TxA<sub>2</sub>).<sup>1,2</sup> The measurement of stable metabolites of TxA<sub>2</sub>, such as urinary 11-dehydro thromboxane B<sub>2</sub>(11dhTxB<sub>2</sub>), allows the determination of the production of TxA<sub>2</sub> by platelets and the assessment of the effectiveness of aspirin therapy.<sup>3-6</sup> This study presents the performance evaluation of a latex-enhanced immunoturbidimetric assay to determine levels of 11dhTxB<sub>2</sub> in human urine.

### METHODOLOGY

The assay is a latex-enhanced immunoturbidimetric assay based on the principle of measuring changes in scattered light as a change in absorbance at 700nm. The latex particles are coated with 11dhTxB<sub>2</sub>, which in the presence of anti-11dhTxB<sub>2</sub> antibody solution, rapidly agglutinate. When a sample containing 11dhTxB<sub>2</sub> is introduced, the agglutination reaction is partially inhibited. The change in absorbance is inversely proportional to the concentration of 11dhTxB<sub>2</sub> in the sample. The assay is applicable to different analysers, in this analytical evaluation the ADVIA 1650 system was used.

### RESULTS

#### Assay range

11dhTxB <sub>2</sub> assay	
Assay range* (pg/ml)	400-6000

131022/TBx

#### Sensitivity

11dhTxB <sub>2</sub> assay		
Limit of blank (pg/ml)	Limit of detection (pg/ml)	Limit of quantitation (pg/ml)
170	238	400

131022/TBx

#### Linearity

11dhTxB <sub>2</sub> assay	
Linearity* (pg/ml)	6250

131022/TBx


\*extended linearity up to 12,000 pg/ml

#### Precision

11dhTxB <sub>2</sub> assay: intra-assay precision		
	Mean concentration (pg/ml)	%CV
Level 1 (n=80)	583	6.2
Level 2 (n=80)	1072	5.9
Level 3 (n=79)	3813	6.5

131016/TBx

Correlation:  
Immunoturbidimetric assay vs  
commercially available assay



$y = 0.983x + 88.9$   
 $r = 0.985$   
 $n = 169$  (urine samples)

131024/TBx



### CONCLUSION

- Data shows optimal performance of the reported assay for the determination of 11dhTxB<sub>2</sub> in urine samples.
- The assay is applicable to different automated analysers and utilises ready-to-use reagents which ensures the reliability and accuracy of the measurements and facilitates the testing procedure.
- The assay is of value as a new analytical tool to predict the effect of aspirin treatment in clinical settings.

### REFERENCES

1. Hamberg, M., et al. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA. 1975, 72: 2994-2998.
2. Ellis, E.F. et al. Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A<sub>2</sub>. Science. 1976, 193: 1135-1137.
3. Chiabrando, C., et al. Urinary excretion and origin of 11-dehydro-2,3-dinor-thromboxane B<sub>2</sub> in man. Prostaglandins. 1993, 45: 401-411.
4. Eikelboom, J.W., et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002, 105: 1650-1655.
5. Foegh, M.L., et al. Urinary thromboxane A<sub>2</sub> metabolites in patients presenting in the emergency room with acute chest pain. J. Intern. Med. 1994, 235: 153-161.
6. Catella, F., et al. 11-Dehydrothromboxane B<sub>2</sub>: a quantitative index of thromboxane A<sub>2</sub> formation in the human circulation. Proc. Natl. Acad. Sci. USA. 1986, 83: 5861-5865.